On March 24 and March 30, entrusted by Zeng Bin, Secretary General of Chengdu High-tech Medical Association and Director of the Medical-Industrial Integration Innovation Center, Bu Wei, Deputy Director of the Medical-Industrial Integration Innovation Center, accompanied CITIC Securities Co., Ltd. and Chengdu Science and Technology Innovation Investment Group respectively. Relevant personnel from the company visited Chengdu Weijin Boao Biomedical Technology Co., Ltd. and conducted in-depth communication.

      Chengdu Weijin Boao Biomedical Technology Co., Ltd. focuses on the treatment and prevention of major immune-related diseases. At the same time, it has a top scientific team and a biopharmaceutical R&D and production enterprise with top technical level. Among them, T-cell lymphoma binding protein has obtained FDA orphan drug And the qualification of rapid review, the pipeline has a number of first-in-class or the best-in-class original innovative drugs in the world, which have important clinical significance.

     Through two in-depth communications, the Institute of Medical-Industrial Integration Innovation Center listed it as an international original biopharmaceutical company with key services in 2022, providing it with comprehensive and in-depth medical-industrial financing and trade and other in-depth services to help The high-tech zone has once again incubated and spawned an international large-scale biopharmaceutical original enterprise.